What types of cancer does Yervoy show particular promise?
Yervoy, also known as ipilimumab, is a monoclonal antibody that has shown significant efficacy in the treatment of certain types of cancer [1]. Developed by Bristol Myers Squibb, Yervoy works by unlocking the brakes on the immune system, allowing it to target and destroy cancer cells.
Melanoma: Yervoy has been approved for the treatment of advanced melanoma, a type of skin cancer that has spread to other parts of the body [2]. In clinical trials, patients who received Yervoy had a significantly higher response rate compared to those who received a placebo or other treatments.
Non-Small Cell Lung Cancer (NSCLC): Yervoy has also been shown to be effective in treating NSCLC, particularly in patients with advanced disease [3]. A study published in the New England Journal of Medicine found that patients who received Yervoy in combination with nivolumab (another immunotherapy drug) had a significantly higher overall survival rate compared to those who received chemotherapy.
Renal Cell Carcinoma (RCC): Yervoy has been investigated as a potential treatment for RCC, a type of kidney cancer [4]. While results have been mixed, some studies have suggested that Yervoy may be effective in treating RCC, particularly in patients with advanced disease.
Other Cancers: Researchers are continuing to explore the potential of Yervoy in treating other types of cancer, including colorectal cancer, breast cancer, and prostate cancer [5].
Why is Yervoy effective in these cancers?
One reason Yervoy excels in these cancers is its ability to target the PD-1/PD-L1 pathway, which is a checkpoint that can suppress the immune system's ability to fight cancer [6]. By blocking this pathway, Yervoy allows the immune system to attack cancer cells more effectively.
Patent and Exclusivity: Yervoy's patent is set to expire in 2027, which may lead to the availability of biosimilars, or generic versions of the drug. However, the patent status and exclusivity period can vary depending on the location and specific use of the drug [7].
Sources:
[1] Bristol Myers Squibb. (2023). Yervoy (ipilimumab) label.
[2] FDA. (2011). Yervoy (ipilimumab) approval.
[3] Reck M, et al. (2016). Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 375(16), 1527-1537.
[4] Motzer RJ, et al. (2015). Nivolumab versus everolimus in patients with advanced renal cell carcinoma: results of a randomized phase 3 trial. Journal of Clinical Oncology, 33(13), 1435-1442.
[5] Bristol Myers Squibb. (2023). Clinical trials for Yervoy (ipilimumab).
[6] Drake CG. (2010). The role of Tim-3 in regulating immune responses. Journal of Leukocyte Biology, 87(1), 143-153.
[7] DrugPatentWatch.com. (2023). Patent expiration date for Yervoy (ipilimumab). https://www.drugpatentwatch.com/patent/US20060042735.